2023-03-29 07:45:00 ET
Viking Therapeutics (NASDAQ: VKTX) , a small-cap biotech, has been on quite the ride over the past few months. Thanks to a positive late-stage trial in nonalcoholic steatohepatitis (NASH) from rival Madrigal Pharmaceuticals (NASDAQ: MDGL) last December, and a strong showing for its experimental obesity treatment VK2735 in a small early-stage study yesterday, Viking's shares have ripped higher by a jaw-dropping 463% over the prior six months.
For further details see:
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run